COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models

Antibodies to watch in 2013

(2013) Janice M Reichert   mAbs

The Role of Anti-Inflammatory Drugs in Colorectal Cancer

(2012) Dingzhi Wang et al.   Annual Review of Medicine

TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types

(2012) Amit Chaudhary et al.   CANCER CELL

Pharmacokinetic evaluation of axitinib

(2012) Brian Patson et al.   Expert Opinion on Drug Metabolism & Toxicology

Why do targeted agents not work in the adjuvant setting in colon cancer?

(2012) Basak Oyan   Expert Review of Anticancer Therapy

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

(2012) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapy—evolving view based on clinical trial results

(2012) Gordon C. Jayson et al.   Nature Reviews Clinical Oncology

Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival

(2012) Xiaoyun Liao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin

(2011) Chi-Ping Day et al.   INTERNATIONAL JOURNAL OF CANCER

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga

(2010) Tilo Grosser et al.   Annual Review of Medicine

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

(2010) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale

(2010) Anil Bagri et al.   TRENDS IN MOLECULAR MEDICINE

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

(2009) M. M. Bertagnolli et al.   Cancer Prevention Research

The nuances of therapy

(2009) Lee M. Ellis et al.   NATURE

Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung

(2009) R. E. Harris   INFLAMMOPHARMACOLOGY

Cyclooxygenase-2 in Cancer and Angiogenesis

(2008) Mehmet Şahin et al.   ANGIOLOGY

Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition

(2008) D. T. Dang et al.   CANCER RESEARCH

Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials

(2008) Scott D. Solomon et al.   CIRCULATION

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

(2008) T. P. Padera et al.   MOLECULAR CANCER THERAPEUTICS

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE